Welcome to our dedicated page for Fonar news (Ticker: FONR), a resource for investors and traders seeking the latest updates and insights on Fonar stock.
FONAR Corporation reports developments tied to its MRI technology business and diagnostic imaging management operations. The company designs, manufactures, sells and services MRI scanners, while Health Management Company of America manages MRI scanners for medical practices in New York and Florida.
Recurring news categories include quarterly operating results, revenue from diagnostic imaging management, product sales, upgrades, service and repair fees, material agreements, shareholder voting matters, capital-structure disclosure and governance matters.
FONAR (NASDAQ:FONR) reported fiscal Q3 2026 results with net income down 25% to $2.3M and EPS down 35% to $0.24, as revenue fell 3% to $26.5M. For the nine months, revenue rose to $78.1M but net income declined 19% to $7.5M.
Cash and short-term investments were $53.8M, working capital was $131.9M, and the current ratio improved to 9.2. MRI scan volume reached record levels. A merger agreement for a proposed going-private transaction is pending shareholder approval on May 28, 2026, and share repurchases remain suspended.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FONAR (NASDAQ: FONR) reported Q2 fiscal 2026 results for the quarter ended December 31, 2025. Total revenue was $25.5M (up 2% YoY) and six-month revenue was $51.6M (up 3% YoY). Quarterly net income rose 15% to $2.5M; diluted EPS was $0.31.
Operating cash flow for the six months fell 52% to $1.9M. On December 29, 2025, the company signed a definitive merger agreement that raised the proposed take-private cash price to $19.00 per share.
FONAR (NASDAQ: FONR) entered a definitive agreement on December 23, 2025 for an all-cash take-private sale to an acquisition group led by CEO Timothy Damadian. Under the Merger Agreement, holders of common stock will receive $19.00 per share at closing; other classes receive $19.00 (Class B), $6.34 (Class C) and $10.50 (Class A non-voting preferred). The $19.00 common share price represents a 31.5% premium to the last close before the announcement and a 39.7% premium to the 90-day average ending June 30, 2025.
The deal is expected to close in Q3 2026, is not subject to financing conditions, requires stockholder approval and will result in delisting from Nasdaq upon closing. Financing includes a $35M debt commitment from OceanFirst Bank plus approximately $10M additional debt and $45M equity from the acquisition group and third parties.
FONAR (NASDAQ: FONR) reported 1Q fiscal 2026 results for the quarter ended September 30, 2025. Total revenues rose 4% to $26.0M, driven by the HMCA diagnostic-imaging segment at $23.5M and FONAR product/services at $2.5M (+14%).
Operating income fell 30% to $3.2M, consolidated net income fell 33% to $2.7M, and diluted EPS declined 26% to $0.34. SG&A increased 33% to $6.8M. Cash and short-term investments were $54.3M at September 30, 2025. HMCA reported scan volume of 55,106 (3.9% YoY growth).
FONAR Corporation (NASDAQ: FONR), a pioneer in MRI technology, reported mixed financial results for fiscal 2025. Total revenues increased 1% to $104.4 million, while net income decreased 24% to $10.7 million. The company's diagnostic imaging subsidiary, HMCA, achieved record scan volume of 216,317 scans, up 3.3% from the previous year.
Key financial metrics include diluted EPS of $1.23 (down 20%), cash and equivalents of $56.3 million, and working capital growth of 4% to $127.5 million. HMCA expanded its operations by adding two MRI scanners, bringing the total to 44 managed scanners across New York and Florida. The company's stock repurchase plan has acquired 373,942 shares for $6.07 million but is temporarily suspended due to a potential "Take Private" transaction.